Seres Therapeutics, Inc.

Vedanta BiosciencesLife SciencesUnited States

72% match

Vedanta Biosciences, Inc. is headquartered in Cambridge, Massachusetts, and develops groundbreaking microbiome-derived immunotherapies and therapeutics to improve patient lives.

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.

Biome ATSBiotechnologySouth Korea

70% match

BiomeBank develops and commercializes microbiome therapeutics designed to restore gut ecological complexity and treat human diseases. The company offers regulated donor-derived therapies, such as BIOMICTRA for recurrent Clostridioides difficile infections, and is advancing a pipeline of next-generation co-cultured microbial products for conditions spanning immunology, metabolism, and oncology. It serves medical practitioners and patients by providing clinically informed gut health treatments.

Spero Therapeutics, Inc.SPRO · BiotechCambridge, United States

70% matchPublic

Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.

Nektar Therapeutics0UNL · BiotechSan Francisco, United States

70% matchPublic

Nektar Therapeutics is a biopharmaceutical firm dedicated to identifying and advancing medical treatments for critical health conditions lacking effective therapies, serving markets across the United States and globally. Its diverse pipeline features several promising candidates: Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma. This same compound is also being investigated in Phase 2 trials for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer, in Phase 1/2A for squamous cell carcinoma of the head and neck, in Phase 1/2 for various solid tumors, and in Phase 1B for COVID-19. Another asset, NKTR-358, a cytokine Treg stimulant, is progressing through Phase 2 clinical trials for systemic lupus erythematosus and ulcerative colitis, alongside Phase 1B studies for atopic dermatitis and psoriasis. Furthermore, NKTR-255, an IL-15 receptor agonist, is undergoing Phase 1/2 clinical trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. The company's portfolio also includes NKTR-262, a toll-like receptor agonist in Phase 1/2 trials for solid tumors, among other developmental drug candidates. Nektar has established significant collaborative agreements with a wide array of pharmaceutical companies, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Founded in 1990, Nektar Therapeutics is headquartered in San Francisco, California.

ClostraBio, Inc.BiotechUnited States

68% matchPrivate

ClostraBio, Inc. is a Chicago-based biotechnology research company pioneering microbiome-based solutions, next-generation probiotics for gut health, and advanced metabolite delivery solutions for inflammatory bowel disease.